SCHEMBL23949507

SCHEMBL23949507

Cc1nc(N2CCOCC2)sc1C(=O)c1cc(C#N)ccc1-c1ncc(CN)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
PIK3CD O00329 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
ALOX5 P09917 2/20 0.42
PTGS2 P35354 1/20 0.42
HTR1A P08908 4/20 0.40
PPARG P37231 2/20 0.38
MAPK1 P28482 2/20 0.37
PKM P14618 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30353339 1.00 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL25058124 0.94 ALDH1A1 (0.44) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL25058696 0.90 ALDH1A1 (0.44) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL25555621 0.88 ALOX5 (0.39) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL25555645 0.88 ALOX5 (0.41) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL25058463 0.85 MAPT (0.43) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL30257323 0.85 PIK3CD (0.38) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL25555662 0.84 PPARG (0.39) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL25555611 0.83 ALOX5 (0.46) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL25058722 0.82 ALOX5 (0.38) ALDH1A1MAPTSMN1; SMN2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
CN-115996910-A Aryl or heteroaryl derivatives 帝人制药株式会社 2023-04-21 CN disclosed
EP-4137481-A1 ARYL OR HETEROARYL DERIVATIVE Teijin Pharma Limited (JP) 2023-02-22 EP disclosed
WO-2021210650-A1 ARYL OR HETEROARYL DERIVATIVE 帝人ファーマ株式会社 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE ARRB1, NR3C2, TRPC6 ALDH1A1 3424/4885MAPT 4747/4885SMN1; SMN2 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.